Christoph Wetz

6PUBLICATIONS
19CO-AUTHORS
Neurology and neuromuscular diseasesPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Satellite-based positioning
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 02, 2024
Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis.

Helena F Pernice, Adrian L Knorz, Paul J Wetzel

|Dec 23, 2023
Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.

Christoph Wetz, Tristan Ruhwedel, Imke Schatka

|Apr 12, 2022
Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [<sup>177</sup>Lu]Lu-DOTATOC.

Markus Galler, Julian M M Rogasch, Kai Huang

|Oct 23, 2021
Added Value of Tomoelastography for Characterization of Pancreatic Neuroendocrine Tumor Aggressiveness Based on Stiffness.

Emin Gültekin, Christoph Wetz, Jürgen Braun

|Feb 10, 2021
The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [<sup>177</sup>Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis.

Tristan Ruhwedel, Julian M M Rogasch, Kai Huang

|May 16, 2019
The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE.

Christoph Wetz, Philipp Genseke, Ivayla Apostolova

Pageof 1

Frequent Collaborators

3 joint publications

Julian M M Rogasch

3 joint publications

Holger Amthauer

2 joint publications

Tristan Ruhwedel

2 joint publications

Kai Huang